An Analysis of Voting and Legislative Behavior. [PDF]
Scibak JW.
europepmc +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
New US State Laws Conflict With ACGME Common Program Requirements. [PDF]
Smith S, Yaghoubian S, Wecksell M.
europepmc +1 more source
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou +2 more
wiley +1 more source
Addressing Physician Shortages in the United States With Novel Legislation to Bypass Traditional Training Pathways: The Fine Print. [PDF]
Abdel-Razig S, Stoller JK, Stoller JK.
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
A Matter of National Security: The Limitations of Contemporary Bioethical and Public Health Approaches for Addressing Enhanced Warfighters. [PDF]
Irfan B, Sirvent R.
europepmc +1 more source
The Influence of Campaign Contributions on the Legislative Process [PDF]
Powell, Lynda W.
core +1 more source
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source

